PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
- Conditions
- Pneumococcal Disease
- Interventions
- Other: Candidate-4Biological: 13vPnCOther: Candidate-2Other: Candidate-3Other: Candidate-5Other: Candidate ControlBiological: PCV15Other: Candidate-1Other: Candidate-6
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 394
- Registration Number
- NCT05489328
- Locations
- 🇺🇸
DM Clinical Research, Tomball, Texas, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Indago Research & Health Center, Inc, Hialeah, Florida, United States
A Study To Describe The Use Of Tofacitinib After Use Of Rituximab In Patients With Rheumatoid Arthritis In A Real-World Setting
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 318
- Registration Number
- NCT05487703
- Locations
- 🇲🇦
Pfizer, Casablanca, Morocco
Real-World Study of Ceftazidime Avibactam in China
- Conditions
- Hospital Acquired PneumoniaVentilator Acquired PneumoniaComplicated Intra Abdominal Infections
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 450
- Registration Number
- NCT05487586
- Locations
- 🇨🇳
The Second People's Hospital of Hebei Medical University, Shijiazhuang, China
🇨🇳Huashan Hospital Fudan University, Shanghai, Shanghai, China
🇨🇳Beijing Tsinghua Changgung Hospital, Beijing, China
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
- Conditions
- COVID-19
- Interventions
- Drug: PF-07321332 (nirmatrelvir)/ritonavir
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT05487040
- Locations
- 🇺🇸
Fresenius Kidney Care-Meridian, Meridian, Idaho, United States
🇺🇸NorthShore University HealthSystem - Glenbrook Hospital, Glenview, Illinois, United States
🇺🇸Fresenius Kidney Care Huntsville, Huntsville, Alabama, United States
A Study to Compare Two Tablet Forms of Tafamidis in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05482308
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT05478603
- Locations
- 🇺🇸
Genesis Clinical Research, LLC, Tampa, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting
- Conditions
- Breast Neoplasms
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 440
- Registration Number
- NCT05478590
- Locations
- 🇵🇱
Ambulatorium Chemioterapii Centrum Onkologii, Bydgoszcz, Poland
🇵🇱Wojewodzki Szpital Zespolony w Elblągu - oddzial onkologii, Elblag, Poland
🇵🇱Oddział onkologii Szpital Specjalistyczny im. H. Klimontowicza, Gorlice, Poland
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12557
- Registration Number
- NCT05477524
- Locations
- 🇺🇸
Hunterdon Medical Center, Flemington, New Jersey, United States
🇺🇸Care Access - Essex, Essex, Connecticut, United States
🇺🇸Care Access Mobile Site, New Shoreham, Rhode Island, United States
Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding
- Conditions
- Non-valvular Atrial Fibrillation
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 120722
- Registration Number
- NCT05471505
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)
- Conditions
- Severe Uncontrolled Atopic Dermatitis
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05466578